文献速递小儿麻醉心胸血管麻醉

纤维蛋白原浓缩物替代冷沉淀在婴儿心脏术后输血算法中的随机对照试验

Fibrinogen Concentrate as an Alternative to Cryoprecipitate in a Postcardiopulmonary Transfusion Algorithm in Infants Undergoing Cardiac Surgery: A Prospective Randomized Controlled Trial.
PubMed 文献 · Anesth Analg · 2020-01-01

本研究为前瞻性随机对照试验,纳入60例小于12月龄的婴儿,在体外循环后输血算法中比较纤维蛋白原浓缩物与冷沉淀。次要结局及不良事件无显著差异。

要点

  • 纤维蛋白原浓缩物可考虑作为冷沉淀替代用于婴儿体外循环后低纤维蛋白原血症。
  • 纤维蛋白原浓缩物组术中异体血制品输注量显著少于冷沉淀组。
  • 两组次要结局及不良事件无显著差异,但安全性仍需进一步研究。

核心结论

  • 在婴儿体外循环后输血算法中,纤维蛋白原浓缩物可考虑作为冷沉淀的替代方案治疗低纤维蛋白原血症。

研究设计与样本

  • 前瞻性随机对照试验,纳入60例小于12月龄在2家三级儿童医院接受非急诊体外循环心脏手术的婴儿,按机构和手术复杂程度分层随机。

主要发现

  • 次要结局(24小时胸管引流量、机械通气时间、不良事件、ICU住院时间、医院住院时间、术后血栓形成及术后30天内死亡)无显著差异。

临床怎么用

  • 对于体外循环后出血伴低纤维蛋白原血症的婴儿,可考虑使用纤维蛋白原浓缩物替代冷沉淀。

局限性

  • 作者指出需要进一步研究评估安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Infants undergoing cardiac surgery are at risk for bleeding and massive transfusion due to an immature coagulation system, complex surgeries, and cardiopulmonary bypass (CPB) effects. Hemodilution from CPB promotes an acquired hypofibrinogenemia that results in impaired fibrin formation, inadequate clot formation, and increased bleeding. In North America, the current standard of care to supplement fibrinogen is cryoprecipitate. An alternative option is the off-label use of fibrinogen concentrate (FC; RiaSTAP; CSL Behring, Marburg, Germany), a purified fibrinogen. Because perioperative allogenic transfusions are associated with increased morbidity and mortality, we sought to determine whether FC would be an acceptable alternative to cryoprecipitate in a post-CPB transfusion algorithm in infants undergoing open-heart surgery. METHODS: We randomized 60 infants (<12 months) undergoing nonemergent cardiac surgery with CPB at 2 tertiary care children's hospitals to receive either cryoprecipitate or FC in a post-CPB transfusion algorithm. Infants underwent a stratified randomization based on institution and surgical complexity. The primary outcome was the difference in number of intraoperative allogenic blood product transfusions. Secondary outcomes included 24-hour chest tube output (CTO), mechanical ventilation time, adverse events (AEs), intensive care unit (ICU) length of stay (LOS), hospital LOS, postoperative thrombosis, and death within 30 days of surgery. The primary analysis followed the intent-to-treat (ITT) principle and was performed using linear regression adjusted for institution and complexity of surgery. A per-protocol (PP) analysis was also performed. RESULTS: Between June 2016 and January 2018, we enrolled 60 patients with complete data available for 25 patients who received cryoprecipitate and 29 patients who received FC. Patients in the cryoprecipitate group (median age: 4 months [2-6 months]) received 5.5 (4.0-7.0) allogeneic blood units in the ITT analysis and 6.0 units (5.0-7.0 units) in the PP analysis. Patients in the FC group (median age: 4 months [2-5]) received 4 units (3.0-5.0 units) in the ITT analysis and 4.0 units (3.0-5.0 units) in the PP analysis. In the adjusted ITT analysis, the FC group received 1.79 units (95% confidence interval [CI], 0.64-2.93; P = .003) less than the cryoprecipitate group. In the adjusted PP analysis, the FC group received 2.67 units (95% CI, 1.75-3.59; P < .001) less than the cryoprecipitate group. There were no significant differences in secondary outcomes or AEs. CONCLUSIONS: Our findings suggest that FC may be considered as an alternative to cryoprecipitate for the treatment of hypofibrinogenemia in infants with bleeding after CPB. Although we found no significant differences between secondary outcomes or AEs, further studies are needed to assess safety.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Downey LA, Andrews J, Hedlin H, et al. Fibrinogen Concentrate as an Alternative to Cryoprecipitate in a Postcardiopulmonary Transfusion Algorithm in Infants Undergoing Cardiac Surgery: A Prospective Randomized Controlled Trial. Anesth Analg. 2020. PMID: 31490252. doi:10.1213/ANE.0000000000004384

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。